Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
The new oral factor Xa inhibitor APXAB is a new type of oral factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. Its trade name is Elelto. It is a new type of oral anticoagulant drug. By inhibiting an important coagulation factor Xa, apixab can prevent thrombin generation and thrombosis.
Product Categories : API Intermediates > Apixaban Intermediate
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.